Not in the right spirit
Mexico’s guidelines on the advertising of alcoholic beverages should be reviewed by the courts because of concerns about their lawfulness, as Daniel Sanchez and Victor Ramirez of Olivares report.
Speeding up the fight against Zika
Brazil’s IP office now expedites patent applications directed to the Zika virus and other neglected diseases, as Ana Paula Jardim and Andréa Granthon of Luiz Leonardos report.
Testing the waters
The UK Intellectual Property Office’s official opinion service on infringement and validity can be a useful tool for parties seeking to file oppositions at the European Patent Office, as Anthony Carlick of Dennemeyer & Associates reports.
Medicine for the millions
Product development partnerships are likely to provide great opportunities for companies seeking to market biosimilar products in Brazil, where there is a huge reliance on public healthcare. Alice Rayol Sandes of Di Blasi, Parente & Associados has more.
Keeping trade fair
As Mexico prepares for a presidential election in 2018, pharma IP owners are hoping that the progress made in trade negotiations is not undone. Hector Chagoya of Becerril Coca & Becerril reports.
Post-grant proceedings: shaping the biotech landscape
It is certain that both inter partes and post-grant reviews will continue to shape the landscape for biologics patents and biosimilars, says Jennifer Fox of Brinks Gilson & Lione.
Patent backlog in Brazil: slow, but welcome, progress
Brazil’s patent backlog has long caused concern for IP owners, particularly those in the pharmaceutical industry, but progress is being made, as Kene Gallois and Ricardo Nunes of Daniel Legal & IP Strategy report.
Can a computer invent a drug?
Artificial intelligence is being used increasingly in the pharma and biotech industries, and questions are being asked about the legal status of innovations created by the technology, as MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch reports.
Uncertain times for antibodies in India
In India, there are two core areas of the antibody patenting field that are unsettled and need correcting, as Archana Shanker and Nupur Maithani of Anand and Anand explain.
A growing business: soybeans in Brazil
Research and development, strong IP rights and good international relations are all factors in Brazil’s rise as a soybean-producing powerhouse, as Gabriel Di Blasi and Matheus Gil do Amaral of Di Blasi Parente & Associados report.
